Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy?

Table 1 Baseline characteristics

	IBD cohort (n = 125)			Non-IBD cohort (n = 213)			P value
mean age +/- SD (yr)	40.3 ± 14.7			50.3 ± 13.4			0.65
	Prep Kit -C	Moviprep	P value	Prep Kit -C	Moviprep	P value
mean ± SD, age (yr)	39.7 ± 14.27	40.9 ± 15.1	0.65	52.98 ± 12.97	53.65 ± 13.98	0.72
Male (n)	35	30	0.13	39	47	0.93

SD: Standard deviation; IBD: Inflammatory bowel disease.

Table 2 Tolerability Scores in the inflammatory bowel disease and non-inflammatory bowel disease cohorts

	Prep Kit-C (n = 145)	Moviprep (n = 143)	P value
IBD, n = 95	9.67 ± 4.87; n = 47	10.89 ± 5.21; n = 48	0.25
Non-IBD, n = 193	11.61 ± 5.32; n = 98	12.32 ± 5.35; n = 95	0.36

IBD: Inflammatory bowel disease.